Operating Lease, Right-of-Use Asset of Taysha Gene Therapies, Inc. from 31 Dec 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Taysha Gene Therapies, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2022 to 30 Sep 2025.
  • Taysha Gene Therapies, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $7,463,000, a 14% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Taysha Gene Therapies, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,463,000 -$1,215,000 -14% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $7,773,000 -$1,198,000 -13% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $8,079,000 -$1,182,000 -13% 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $8,381,000 -$1,201,000 -13% 31 Dec 2024 10-Q 04 Nov 2025 2025 Q3
Q3 2024 $8,678,000 -$1,174,000 -12% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $8,971,000 -$1,377,000 -13% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $9,261,000 -$1,386,000 -13% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $9,582,000 -$1,361,000 -12% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $9,852,000 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $10,348,000 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $10,647,000 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $10,943,000 31 Dec 2022 10-K 19 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.